Prospective study of Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration in Japanese Patients

Prospective study of Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration in Japanese Patients - Ranibizumab for Exudative Age-Related Macular Degeneration

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027799

Enrollment

Registered

2017-06-18

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exudative Age-Related Macular Degeneration

Interventions

Ranibizumab

Monthly (3 times) to PRN regimen Ranibizumab

Monthly (3 times) to Treat and Extend regimen Ranibizumab

Monthly (3 times) to Treat and Extend regimen followed by Aflibercept

Treat and Extend regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) naive neovascular AMD with older than 50 years and acceptance of this study 2) typical AMD

Exclusion criteria

Exclusion criteria: 1) previous treatment for AMD 2) polypoidal choroidal vasculopathy 3) retinal angiomatous proliferation 4) diabetic maculopathy, retinal vascular occlusion, or idiopathic macular telangiectasia

Design outcomes

Primary

Measure	Time frame
The mean changes of best-corrected visual acuity at month 24 compared with baseline	—

Secondary

Measure	Time frame
The prevalence of eyes with only ranibizumab by PRN (pro re nata)	—

Countries

Japan

Contacts

Public ContactMasaaki Saito

Akita University Department of Ophthalmology

masaaki@med.akita-u.ac.jp018-834-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026